X

Trial Profile

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Zanzalintinib (Primary) ; Regorafenib
Indications Adenocarcinoma; Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms STELLAR-303
Sponsors Exelixis

Most Recent Events

06 Aug 2024 According to an Exelixis media release, company anticipates preliminary results from the study to readout in 2025
06 Aug 2024 According to an Exelixis media release, company announced that enrollment has been completed in the STELLAR-303 phase 3 pivotal study.
06 Aug 2024 According to an Exelixis media release, study status changed from recruiting to active, no longer recruiting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com